India: Race To The Generic Launch

Last Updated: 15 May 2019
Article by Rebecca Mathai

Introduction

In a bid to delay the launching of generic drugs, the multinational drug manufacturers have recently asked the Indian government to develop a registry which will have all the collated information regarding drug applications pending manufacturing and marketing approval. This is not the first time that these pharma giants have tried hindering the process of generic drug development. Previously, there was an attempt to prevent generic drug players from conducting research and development during the life of the patent. This would in-turn lead to a delay in the marketing of the generic drug after the patent expiry of the brand company's drug. In the US, this is not possible because of the Hatch-Waxman provision which encourages competition and lower prices and allows generic companies to conduct experiments using safety and effectiveness studies of the innovator during the life of the patent. Furthermore, in the US there is an on-going effort to pass CREATES Act, which proposed that a generic drug manufacturer would be entitled to file a civil action against an innovator drug company if the latter refuses to make available enough samples of a product for testing. However, no such legislation protecting generic players has been passed as of yet in India.

Some other tactics which have been employed as aforesaid by innovator companies across various jurisdictions are:-

1) Filing multiple divisional patent applications with trivial modifications to the parent patent application

Since extending the sales and protection of blockbuster drugs as much as possible is of paramount importance, innovator companies may file multiple divisional applications of the parent application so as to hinder generic entry for a long time. Such patent clusters also cause uncertainty and obscurities with regards to the patent status of a drug product. Generic companies could initiate invalidation proceedings of such patents, but refrain from doing so taking into consideration the time and money to be invested. Patent ever-greening is a prevalent practice adopted by innovator companies in the US since second use, new dosage form or route of administration, polymorph, salt etc. of an active ingredient can be patented to extend the life of a patent family. An example of second medical use patenting can be that of duloxetine (marketed by Eli Lilly) which initially received protection for treatment of major depressive disorder, but eventually went on to receive patents for other uses like fibromyalgia, neuropathic pain, eating disorders etc.

A classic example of patent ever-greening can be that of atorvastatin, a block buster drug sold by Pfizer Inc. under the brand name Lipitor. The first generic patent for the class of HMG-CoA inhibitors filed in 1986 expired in 2010. A specific patent US5273995 for atorvastatin calcium filed in 1991 expired in 2011 giving an additional year of exclusive rights to market the drug. To further extend market rights, another patent US5969156 was filed in 1996, disclosing atorvastatin polymorphic forms I, II and IV which expired recently in 2017. Therefore, a total of six additional years of protection over the original patent expiry was obtained by this ever-greening strategy. In India, section 3 (d) prevents patenting of salts, esters, ethers and other few forms of a known substance unless enhanced therapeutic efficacy is proven. However, pharma companies are at times able to find loopholes even in this provision.

2) FDA Citizen petitions

It is a common practice for pharmaceutical companies in the US to file citizen petitions impeding approval of ANDAs (Abbreviated New Drug Application) and 505 (b) (2) applications. A citizen petition is usually submitted to the FDA requesting changes in health policy or in genuine cases like amending or revoking an order or regulation and any other administrative action. This provision has been widely misused by innovator companies in cases like:-

(i) determining if a generic drug is the same as the reference listed drug (RLD)

(ii) designation of an additional reference standard (RS) for a drug if the current RLD/ RS are not available in the market for testing purposes

(iii) assigning schedule V to a particular drug product

(iv) requesting the FDA to refrain from receiving or approving any ANDA that references the NDA of the innovator, unless the ANDA sponsor provides data consistent with the requirements set forth in the petition for establishing bioequivalence

(v) determining if an RLD was withdrawn from the market for safety and efficacy reasons.

(vi) whether a drug is suitable for submission in an ANDA

However, section 505 (q) of the FD&C Act provides that citizen petition may not delay the approval of a generic drug, unless it is observed that such delay is necessary to protect the public health. In the US, 179 CPs were filed in the year 2018 and a gradual increase in its filings has been observed over the previous years.

An example of such a case is the citizen petition filed by TherapeuticsMD, Inc. on December 11, 2018 requesting the FDA to refrain from receiving or approving any ANDA that references Imvexxy" (estradiol vaginal inserts), NDA #208564, unless the ANDA sponsor provides data consistent with the requirements set forth in this petition for establishing bioequivalence ("BE"). TherapeuticsMD submits this petition seeking issuance of an appropriate BE guidance for Imvexxy.

3) Weakness in the opposition procedure

This is mostly to do with the time taken by the Controller in reaching a decision with respect to the opposition proceedings.

4) Compulsory licensing

The only ever case of compulsory license being granted in India was to Natco Pharma. Innovator companies walk away scot-free without making life-saving drugs available in sufficient quantities and at reasonable prices to the public as also evidenced by the fact that there is no timely filing of Form 27 as per the working requirement of the Indian Patent Act. If compulsory licenses are not granted to remedy such wrong-doings, how will generic companies be able to bring out generic versions to help the public at large?

5) Litigation settlements between innovator and generic companies

Distribution of authorized generics by an innovator company, its affiliate or a generic distributor after patent term expiry reduces market share which should ideally be covered by generic companies. An interesting case of the aforementioned has been by Valeant Pharma which launched authorized generic of diabetes drug Glumetza (Metformin) in the US. Lupin had already enjoyed a 180-day exclusivity pursuant to a P-IV filing. The launch of the authorized generic by Valeant not only ate into Lupin's market share for the drug but also ended up increasing competition and prices. It is not uncommon to hear of settlements in the form of reverse payments or potential licenses between P-IV filers and innovators which tactfully averts the launch of generics to a later date. The Restasis case is an epitome of a controversial license tactic gone sourly wrong, otherwise known as the sovereign immunity case. Allergan licensed its patent to the St. Regis Mohawk Indian Tribe and tried to shield its patents from IPR challenges filed by Mylan, Teva and Akorn using tribal sovereign immunity. However, Allergan did not succeed and its patents stand invalidated.

Conclusion

In view of the above, it can be inferred that innovator companies can go to any extent to protect their patents. Who is to say what will happen if the pending drug application registry is made available to innovator companies and what strategies they will employ to quash attempts by the generic manufacturers to launch their version. The government will have to take efforts to ensure that it does not encourage its use for unnecessary litigation.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions